Abstract
Vaccination against human papillomavirus (HPV) reduces the prevalence of oral infection by an estimated 88% among young adults in the United States, a protection that could help reduce rates of HPV-related oropharyngeal cancers, according to data that will be presented at the American Society of Clinical Oncology Annual Meeting in Chicago, IL. However, the population-level benefit will remain low unless more people get vaccinated.
©2017 American Association for Cancer Research.
MeSH terms
-
Female
-
Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18 / therapeutic use*
-
Humans
-
Mouth / drug effects
-
Mouth / virology
-
Oropharyngeal Neoplasms / epidemiology
-
Oropharyngeal Neoplasms / prevention & control*
-
Oropharyngeal Neoplasms / virology
-
Papillomavirus Infections / epidemiology
-
Papillomavirus Infections / prevention & control*
-
Papillomavirus Infections / virology
-
Papillomavirus Vaccines / therapeutic use*
-
United States
-
Uterine Cervical Neoplasms / epidemiology
-
Uterine Cervical Neoplasms / prevention & control
-
Uterine Cervical Neoplasms / virology
Substances
-
Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18
-
Papillomavirus Vaccines